Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients.
The purpose of this study was to examine the efficacy and tolerability of ezetimibe in cardiac transplant recipients who were intolerant of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) or unable to reach target lipid levels with statin therapy. After treatment with ezetimibe (n = 16), mean total and low-density lipoprotein cholesterol levels decreased significantly (228 +/- 40 mg/dl to 197 +/- 48 mg/dl, p = 0.003; and 149 +/- 34 mg/dl to 117 +/- 39 mg/dl, p < 0.001, respectively). One patient required a reduction in ezetimibe dose owing to myalgias; no other adverse events occurred. This initial experience indicates that ezetimibe is well tolerated in cardiac transplant recipients and is effective in reducing total and low-density lipoprotein cholesterol levels.
Patel
Ayan R
AR
Heart Failure and Cardiac Transplant Center, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA. apatel@tufts-nemc.org
Ambrose
Marietta S
MS
Duffy
Gretchen A
GA
Cote
Heather
H
DeNofrio
David
D
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use*; D000069438:Ezetimibe; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008074:Lipoproteins / Q000037:antagonists & inhibitors / Q000097:blood; D008077:Lipoproteins, LDL / Q000037:antagonists & inhibitors / Q000097:blood; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced
D000924:Anticholesteremic Agents; D001384:Azetidines; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D000069438:Ezetimibe